PFE Stock Pfizer Inc - Complete Overview

Nyse / Pharmaceutical Products / Healthcare / PFE Stock

Pfizer Inc (PFE) price per share as of 13 Jul 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 5.85B
Avg Daily Volume 19.99M
Market Cap 204.97B
Volatility 17.08% LOW

PFIZER INC (PFE) OVERVIEW

PFE stock is a pharmaceutical products company traded on Nyse. It is valued at 204.97B US dollars. There are 5.85B shares outstanding which Pfizer Inc issued to investors. Volatility of the stock is LOW, and the daily volume is 17.08% stock on average. Pfizer Inc is paying dividends with the latest yield of 3.80%. It brought investors a total return of 18.19% over the last 12 months. Pfizer Inc stock is relatively cheap. It's P/E ratio is below the market average.

Pfizer Inc (PFE) STOCK PRICE PERFORMANCE

PFE SHAREHOLDER'S RETURN

Earnings Per Share 3.66
Dividends Per Share 1.32
12 Months Price Performance High
Dividend Yield Low
Total Return High

PFE LATEST NEWS

Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?

Is (PFE) Outperforming Other Medical Stocks This Year?

4 Things You Need to Know About Pfizer's Restructuring Plans

What's behind the big pharma company's big reorg?

Pfizer to reorganize into 3 business units, including a new hospital medicines business

Pfizer Inc. announced Wednesday a plan to reorganize into three businesses, including a new hospital business unit for anti-infectives and sterile injectables. The new hospital medicines unit will be part of Innovative Medicines, which will also include all of the current innovative health units and biosimilars. The other units will be Established Medicines, which will include most off-patent solid oral dose legacy grands, including Lyrica, Lipitor and Viagra, and certain generic medicines; and Consumer Healthcare, which will include all over-the-counter medicines. The changes will be effective at the beginning of fiscal 2019. The company said the changes come with the expected "significant reduction in the impact of patent protection losses post-2020 following the loss of exclusivity for Lyrica in the U.S., which is expected to occur in or after December 2018." Pfizer said the changes aren't expected to affect capital allocation priorities or 2018 financial guidance. The stock slipped 0.4% in premarket trade. It has gained 3.3% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has climbed 5.2% and the Dow Jones Industrial Average has tacked on 0.8%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Drug giant Pfizer to split into three units, including a new hospital business

Drug giant Pfizer on Wednesday said it plans to split into three businesses.

If You're Retired, Consider Buying These 3 Stocks

These stocks check off all the boxes for retired investors.

Pfizer says it will postpone price increases after discussions with Trump

Pfizer announced on Tuesday it would postpone drug price hikes after an "extensive" conversation between the company's CEO and President Donald Trump.

Pfizer Inc (PFE) TECHNICAL INDICATORS

Name Value Action
RSI(14) 70.08 Overbought
CMO(14) 40.16 Strong buy
ADX(14) 16.96 N/A
Williams %R -3.77 Sell

PFE STOCK VALUATION

PFE Industry Sector Market
Price to Earnings 9.57 58.99 86.82 29.24
Price to Book Value 2.92 4.24 4.45 3.48
Price to Sales 3.89 3.40 4.04 3.26
Return on Equity 33.40% 14.07% 14.08% 15.51%
Return on Assets 12.80% 6.17% 6.88% 5.81%
All values TTM (trailing twelve months). Source: Quandl.com

PFE FORUM DISCUSSIONS